Vapotherm Inc. Stock News

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its propriet

Vapotherm has seen a boom induced by the pandemic reverse violently. The pandemic has not boosted Vapotherm's business, as losses have only increased during this period of time.

Vapotherm, Inc. (NYSE:VAPO ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Mark Klausner - Westwicke Partners Joseph Army - CEO, President & Director John Landry - SVP,

Vapotherm (VAPO) delivered earnings and revenue surprises of -38.10% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vapotherm Inc (NYSE: VAPO) expects Q1 FY22 sales of $20.5 million - $21.5 million, lower than $32.3 million in Q1 FY21 and the consensus of $25.78 million. Vapotherm also announced the withdrawal of

Vapotherm, Inc. (VAPO) CEO Joe Army on Q4 2021 Results - Earnings Call Transcript

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its innovati

Vapotherm, Inc. (VAPO) CEO Joe Army on Q3 2021 Results - Earnings Call Transcript

Vapotherm (VAPO) delivered earnings and revenue surprises of -4.00% and 17.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Vapotherm (NYSE:VAPO) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its propriet

Vapotherm Inc (NYSE: VAPO) expects FY21 revenue of at least $102 million, an increase of $17 million over the low end of previous guidance of $85 million - $91 million. Related Content:   FDA Give

The FDA has granted 510(k) clearance to Vapotherm Inc's (NYSE:VAPO) HVT (high-velocity therapy) 2.0. Vapotherm high-velocity therapy is mask-free noninvasive ventilatory support and is a front-lin

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2